Business Wire

European Medicines Agency Validates Pierre Fabre’s Application for Combination of BRAFTOVI® (encorafenib), MEKTOVI® (binimetinib) and cetuximab for the Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer

Share

Pierre Fabre today announced that the European Medicines Agency (EMA) has validated for review the filing of Type II variation applications for BRAFTOVI ® (encorafenib) + MEKTOVI ® (binimetinib) in combination with cetuximab for the treatment of patients with BRAFV600E -mutant metastatic colorectal cancer (mCRC). Validation of the applications confirms the submission is complete, and the EMA will now begin its review procedure.

BRAF-mutant mCRC is a devastating cancer, for which there are currently limited treatment options that can prolong the lives of patients. The acceptance of our application by the EMA brings us one step closer to realising our commitment towards advancing care for patients living with difficult-to-treat cancers,” said Jean-Luc Lowinski, CEO of the Pierre Fabre Pharmaceuticals Division. “If approved, BRAFTOVI+MEKTOVI in combination with cetuximab has the potential to be the first chemotherapy-free, targeted regimen for patients with BRAFV600E -mutant mCRC.”

The application is based on data from the pivotal Phase 3 BEACON CRC trial. The randomised, open-label, global study evaluates the efficacy and safety of BRAFTOVI+MEKTOVI in combination with cetuximab in patients with advanced BRAFV600E -mutant mCRC whose disease has progressed after one or two prior lines of therapy. This is a first-of-its-kind study, as the trial is designed to test combined BRAF/MEK targeted therapies in individuals with BRAF-mutant mCRC.1 Expanded interim results from this trial were previously presented during a late-breaking oral session at the 2019 European Society for Medical Oncology (ESMO) Congress and simultaneously published online in the New England Journal of Medicine in September 2019.

The results of the BEACON CRC trial showed significant improvements in overall survival (OS) and objective response rates (ORR) for BRAFTOVI+MEKTOVI in combination with cetuximab and BRAFTOVI in combination with cetuximab, compared with cetuximab plus irinotecan-containing regimens. Both combination regimens demonstrated a safety profile with no unexpected toxicities.2

Patients with BRAF-mutant CRC generally have a poor prognosis with current available treatments. Currently, there are no approved therapies in Europe specifically indicated for this high medical need population.3–10 BRAF mutations are estimated to occur in approximately 8-12% of patients with mCRC, and V600E is the most common mutation.11–19

About Colorectal Cancer
Worldwide, colorectal cancer is the third most common type of cancer in men and the second most common in women, with approximately 1.8 million new diagnoses in 2018. Globally in 2018, approximately 881,000 deaths were attributed to colorectal cancer.20 Every year more than 450,000 people in Europe are diagnosed with colorectal cancer and approximately 230,000 will die of their disease.21 BRAF mutations are estimated to occur in approximately 8-12% of patients with mCRC and represent a poor prognosis for these patients.11-18,22 The V600E mutation is the most common BRAF mutation and the risk of mortality in CRC patients with the BRAFV600E mutation is more than two times higher than for those with wild-type BRAF.19,21,23

About BEACON CRC
BEACON CRC is a randomised, open-label, global trial evaluating the efficacy and safety of BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) in combination with cetuximab in patients with BRAFV600E -mutant mCRC whose disease has progressed after one or two prior regimens. BEACON CRC is the first and only Phase 3 trial designed to test a BRAF/MEK combination targeted therapy in BRAFV600E -mutant mCRC. Thirty patients were treated in the safety lead-in and received BRAFTOVI+MEKTOVI in combination with cetuximab (BRAFTOVI 300 mg daily, MEKTOVI 45 mg twice daily and cetuximab per label). Of the 30 patients, 29 had a BRAFV600 mutation. Microsatellite instability high, resulting from defective DNA mismatch repair, was detected in only one patient. As previously announced, BRAFTOVI+MEKTOVI in combination with cetuximab showed an acceptable safety profile that supported initiation of the randomised portion of the trial. The randomised portion of the BEACON CRC trial is designed to assess the efficacy of BRAFTOVI in combination with cetuximab with or without MEKTOVI compared with cetuximab and irinotecan-based therapy. 665 patients were randomised 1:1:1 to receive BRAFTOVI+MEKTOVI in combination with cetuximab, BRAFTOVI in combination with cetuximab or the control arm (irinotecan-based therapy and cetuximab). The study was amended to include an interim analysis of endpoints, including ORR. The primary OS endpoint is a comparison of BRAFTOVI+MEKTOVI in combination with cetuximab with the control arm. Secondary endpoints address efficacy of BRAFTOVI in combination with cetuximab compared with the control arm and compared with BRAFTOVI+MEKTOVI in combination with cetuximab. Other secondary endpoints include progression-free survival, duration of response, safety and tolerability. Health-related quality of life data will also be assessed. The trial is being conducted at over 200 investigational sites in North America, South America, Europe and the Asia-Pacific region. The BEACON CRC trial is being conducted with support from Pierre Fabre, Ono Pharmaceutical Co. Ltd., and Merck KGaA, Darmstadt, Germany (support is for sites outside of North America).

About BRAFTOVI® (encorafenib) and MEKTOVI® (binimetinib)
BRAFTOVI® (encorafenib) is an oral small-molecule BRAF kinase inhibitor and MEKTOVI® (binimetinib) is an oral small-molecule MEK inhibitor that target key enzymes in the MAPK signalling pathway (RAS-RAF-MEK-ERK). Inappropriate activation of proteins in this pathway has been shown to occur in many cancers, including melanoma, colorectal cancer, non-small cell lung cancer and others. The combination of BRAFTOVI+MEKTOVI is currently only approved for use in unresectable or metastatic melanoma with a BRAFV600 mutation. The use of BRAFTOVI+MEKTOVI in combination with cetuximab for the treatment of patients with BRAFV600E -mutant mCRC is investigational and not approved by the European Commission (EC).

On 20 September 2018, the EC granted marketing authorisation for the combination of BRAFTOVI and MEKTOVI for the treatment of adult patients with unresectable or metastatic melanoma with a BRAFV600 mutation, as confirmed by a validated test.24,25 The EC decision is applicable to all 28 European Union member states plus Iceland, Liechtenstein and Norway. BRAFTOVI and MEKTOVI have also received regulatory approval in the United States (U.S.), Australia and Japan. On 27 June 2018, the combination of BRAFTOVI and MEKTOVI was approved by the FDA for the treatment of unresectable or metastatic melanoma with a BRAFV600E or BRAFV600K mutation, as detected by an FDA-approved test.26,27 BRAFTOVI and MEKTOVI are not indicated for treatment of patients with wild-type BRAF melanoma. In Japan, the combination is approved for unresectable melanoma with a BRAF mutation. BRAFTOVI and MEKTOVI have received regulatory approvals in Australia and Switzerland for BRAFTOVI and MEKTOVI for the treatment of unresectable melanoma with a BRAF mutation submitted by Pierre Fabre.

Pfizer has exclusive rights to BRAFTOVI® and MEKTOVI® in the U.S. and Canada. Pfizer has granted Ono Pharmaceutical Co. Ltd. exclusive rights to commercialise both products in Japan and South Korea, Medison exclusive rights to commercialise both products in Israel and Pierre Fabre exclusive rights to commercialise both products in all other countries, including Europe, Latin America and Asia (excluding Japan and South Korea).

About Pierre Fabre
With a portfolio representing a continuum of activities spanning from prescription drugs and consumer healthcare products to dermo-cosmetics, Pierre Fabre is the 2nd largest dermo-cosmetics laboratory in the world, the 2nd largest private French pharmaceutical group and the market leader in France for products sold over the counter in pharmacies. Its portfolio includes several global brands and franchises among which Eau Thermale Avène, Klorane, Ducray, René Furterer, A-Derma, Galénic, Elancyl, Naturactive, Pierre Fabre Health Care, Pierre Fabre Oral Care, Pierre Fabre Dermatologie and Pierre Fabre Oncologie.

In 2018, Pierre Fabre generated 2.3 billion euros in revenues, of which 64% came from its international business and 61% from its dermo-cosmetics division. Pierre Fabre, which has always been headquartered in the South-West of France, counts about 11,000 employees worldwide, owns subsidiaries and offices in over 40 countries and enjoys distribution agreements in over 130 countries. In 2018, Pierre Fabre dedicated 187 million euros to R&D efforts, split between oncology, dermatology, consumer healthcare and dermo-cosmetics.

Pierre Fabre is 86%-owned by the Pierre Fabre Foundation, a government-recognised public-interest foundation, and secondarily by its own employees through an international employee stock ownership plan.

In 2019, Ecocert Environment assessed the Group’s corporate social and environmental responsibility approach according to the ISO 26000 standard on sustainable development and awarded it the ECOCERT 26000 “Excellence” level.

www.pierre-fabre.com
@PierreFabre

References
[1] ASCO Post. BEACON CRC: Encorafenib/Binimetinib/Cetuximab Improves Survival in BRAF V600E–Mutated Metastatic Colorectal Cancer. Available at: https://ascopost.com/issues/august-10-2019/beacon-crc/. Accessed November 2019.
[2] Tabernero J, et al. ESMO 2019 (Abstract No. LBA32).
[3] Saridaki Z, et al. PLoS One. 2013;8(12):e84604.
[4] Loupakis F, et al. Br J Cancer. 2009;101(4):715–21.
[5] Corcoran RB, et al. Cancer Discov. 2012;2(3):227–35.
[6] Kopetz S, et al. J Clin Oncol. 2017;35(15 suppl):3505.
[7] De Roock W, et al. Lancet Oncol. 2010;11(8):753–62.
[8] Ulivi P, et al. J Transl Med. 2012;10:87.
[9] Peeters M, et al. J Clin Oncol. 2014;32(15 suppl):3568.
[10] Ardekani R, et al. PLoS One. 2012;7(7):e40506.
[11] Maughan TS, et al. Lancet. 2011;377:2103–14.
[12] Souglakos J, et al. Br J Cancer. 2009;101:465–72.
[13] Richman SD, et al. J Clin Oncol. 2009;27:5931–7.
[14] Tran B, et al. Cancer. 2011;117:4623–32.
[15] Yokota T, et al. Br J Cancer. 2011;104:856–62.
[16] Tie J, et al. Int J Cancer. 2011;128:2075–84.
[17] Loupakis F, et al. Br J Cancer. 2009;101:715.
[18] Tviet KM, et al. J Clin Oncol. 2012;30:1755–62.
[19] Sclafani F, et al. Crit Rev Oncol Hematol. 2013;87:55–68.
[20] The Global Cancer Observatory, 2018. International Agency for Research on Cancer, World Health Organization. Available at: https://gco.iarc.fr/today/online-analysis-multi-bars. Accessed November 2019.
[21] Colorectal Cancer in Europe: A Framework for Improving Outcomes for Patients. EuropaColon. Available at: https://webgate.ec.europa.eu/chafea_pdb/assets/files/pdb/20124301/20124301_d04-00_en_ps_ecwhitepaper.pdf. Accessed November 2019.
[22] Vecchione L, et al. Cell. 2016;165(2):317–30.
[23] Safaee Ardekani G, et al. PLoS One. 2012;7(10):e47054.
[24] European Medicines Agency. BRAFTOVI® (encorafenib) Summary of Product Characteristics. Available at: https://www.ema.europa.eu/documents/product-information/braftovi-epar-product-information_en.pdf. Accessed November 2019.
[25] European Medicines Agency. MEKTOVI® (binimetinib) Summary of Product Characteristics. Available at: https://www.ema.europa.eu/documents/product-information/mektovi-epar-product-information_en.pdf. Accessed November 2019.
[26] Array BioPharma. BRAFTOVI® (encorafenib) US Prescribing Information 2018. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210496lbl.pdf. Accessed November 2019.
[27] Array BioPharma. MEKTOVI® (binimetinib) US Prescribing Information 2019. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210498s001lbl.pdf. Accessed November 2019.

Contact information

Pierre Fabre
Valérie Roucoules
(33) 1 49 10 83 84
valerie.roucoules@pierre-fabre.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Piper Sandler Advises Momentive Performance Materials on the Sale of its Consumer Sealants Business to Henkel Corporation7.8.2020 21:55:00 EESTPress release

Piper Sandler &Co., a leading investment bank and institutional securities firm, served as financial advisor to Momentive Performance Materials Inc. (Momentive) in the sale of its consumer sealants business to Henkel Corporation. The deal, which remains subject to customary closing conditions including regulatory clearances, is expected to close in 2020. Momentive’s consumer sealants business encompasses GE-branded consumer sealants sold under license from the General Electric Company and available through home-improvement centers, major retailers and hardware stores. Momentive will continue to manufacture consumer sealants through 2021 under a transition supply agreement. (Source: Momentive Performance Materials Inc.) “In the midst of a pandemic, we are delighted to have helped Momentive, reach this agreement and achieve the goals of the company and its shareholders,” said Telly Zachariades, managing director, chemicals and materials, at Piper Sandler. “We are looking forward to aidin

ENA Investment Capital Publishes Open Letter to Ontex Shareholders7.8.2020 14:00:00 EESTPress release

ENA Investment Capital (“ENA”), a long-term, value-oriented investment firm and the second-largest shareholder in Ontex Group NV (“Ontex” or the “Company”) owning c.15% of the Company’s outstanding shares, today issued the following public letter to Ontex’s shareholders. Dear Fellow Ontex Shareholders, ENA Investment Capital, owning c.15% of the voting shares of Ontex, has devoted considerable time and resources to conduct a thorough analysis of Ontex. This includes acquiring a comprehensive understanding of the personal hygiene segment and, more importantly, of the Company’s turnaround potential which we are convinced, if effectively executed, can deliver significant value for shareholders. As part of this extensive 18-month due diligence effort, we have consulted with former executives from Ontex as well as its main competitors, industry experts, investment bankers, lawyers and specialist consultants on a wide range of topics critical to Ontex’s business such as raw material trends a

Novavax and Takeda Announce Collaboration for Novavax’ COVID-19 Vaccine Candidate in Japan7.8.2020 12:28:00 EESTPress release

Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, and Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK), today announced a partnership for the development, manufacturing and commercialization of NVX‑CoV2373, Novavax’ COVID‑19 vaccine candidate, in Japan. NVX‑CoV2373 is a stable, prefusion protein made using Novavax’ recombinant protein nanoparticle technology and includes Novavax’ proprietary Matrix‑M™ adjuvant. Takeda will receive funding from the Government of Japan’s Ministry of Health, Labour and Welfare (MHLW) to support the technology transfer, establishment of infrastructure and scale-up of manufacturing. Takeda anticipates the capacity to manufacture over 250 million doses of the COVID-19 vaccine per year1. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200807005160/en/ “Takeda’s leading position in Japan, technical expertise,

SES S.A.: Half Year 2020 Results7.8.2020 08:30:00 EESTPress release

SES S.A. announced financial results for the six months ended 30 June 2020. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200806006164/en/ SES S.A.: Half Year 2020 Results (Photo: Business Wire) Solid H1 performance in line with expectations and continued underlying growth in Networks of +7.1% year-on-year(1,2) Revenue of EUR 947.5 million, -1.5% as reported with underlying revenue 2.4%(1,2) lower than H1 2019 Adjusted EBITDA(3) of EUR 582.0 million, -2.3% as reported (-3.5% at constant FX(2)) compared with H1 2019 and representing an Adjusted EBITDA(3) margin of 61.4% including a 2.2% year-on-year reduction in recurring operating expenses Limited COVID-19 impact in H1 reflecting business resilience with measures in place to mitigate increased headwinds in H2 2020 Updated FY 2020 group revenue outlook to EUR 1,860 - 1,900 million(4) in view of expected COVID-19 related revenue development FY 2020 Adjusted EBITDA(3) outlook

Western Union Stands in Solidarity with Lebanon6.8.2020 23:47:00 EESTPress release

Western Union, a leader in cross-border, cross-currency money movement and payments, today announced that it is offering zero-feei international money transfers paid out in U.S. dollars to Lebanon, as the country grapples with its recent tragedy amidst other economic and pandemic related threats. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200806006068/en/ Western Union Stands in Solidarity with Lebanon; Money Transfers to Lebanon Zero-Fee Paid out in US Dollars (Graphic: Business Wire) “We stand in solidarity with the people of Lebanon as they confront this latest tragedy following the horrific explosion in Beirut on August 4. Our thoughts and prayers are with families of those injured and have lost their lives,” said Jean Claude Farah, President, Global Network, Western Union. Farah said: “We know the people of Lebanon will stand strong as they grapple with this latest issue amidst other pressures of economic and COVID-

Pacific Drilling Announces Second-Quarter 2020 Results; Pacific Sharav Awarded a New 10-Well Contract in U.S. Gulf of Mexico6.8.2020 23:04:00 EESTPress release

Pacific Drilling S.A. (NYSE: PACD) (“Pacific Drilling” or the “Company”) today reported results for the second quarter of 2020. Net loss for second-quarter 2020 was $87.4 million or $1.16 per diluted share, compared to net loss of $61.0 million or $0.81 per diluted share in first-quarter 2020. Pacific Drilling CEO Bernie Wolford commented, “In the second quarter, our crews and leadership continued to exemplify our commitment to safe and efficient operations, including adopting measures to manage risks associated with COVID-19 transmission, delivering exceptional results for our clients, efficiently preserving the value of our assets and significantly reducing overhead costs.” Mr. Wolford continued, “Although oil prices began to rebound during the second quarter, clients have generally reduced their drilling investments, as evidenced by Equinor’s decision to cancel the previously exercised third firm well for Pacific Khamsin, and Murphy’s decision to cancel the two well Mexico contract

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom